Loading
Much of trial screening is paperwork, questions and reviewing scans that already exist. Doing this by video and electronic consent before any travel would let patients decide without a wasted trip.
Sites adopt electronic consent with teach-back, tele-screening visits reviewing existing imaging and pathology via central read, and remote collection of history and performance status, so in-person attendance is needed only for procedures the protocol genuinely requires. Regulators in the US and EU accept eConsent; adoption in oncology remains low.
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).